FDA Advisory Panel Recommends Compounding Access for 6 Peptides — 5 of Them Already in Our Library
Regulatory UpdateOn July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met and voted on whether to recommend adding several peptides to the FDA's 503A Bulks List — the list that governs which substances compounding pharmacies are legally permitted to use. The committee voted in favor of six: BPC-157, KPV, TB-500, and MOTS-c on July 23 (each roughly 7-8 votes in favor to 5-6 against, with abstentions), and Semax and epitalon on July 24 by tighter margins. A seventh candidate, emideltide (a delta sleep-inducing peptide not currently in our library), was voted down.
What this actually means: this is a nonbinding advisory recommendation, not an FDA decision. Nothing about any of these compounds' legal status has changed as a result of this vote. The FDA has not added anything to the 503A Bulks List, none of these compounds is FDA-approved, and the agency must still decide whether to proceed through formal notice-and-comment rulemaking before compounding pharmacies could legally use them under this pathway. Precedent exists for the FDA to disagree with PCAC recommendations.
Worth weighing before reading too much into a "yes" vote: according to reporting on the meeting, the FDA's own agency scientists opposed several of these recommendations, and a majority of the panelists who voted in favor reportedly have ties to the peptide industry. Both are relevant context for how much signal to take from this committee's vote alone.
Why we're covering this: five of the six recommended compounds are already in our Peptide Library — BPC-157 · KPV · TB-500 · MOTS-c · Epitalon. We've added a dated "Recent development" note to each of their regulatory-status sections so nothing on those pages reads as out-of-date now that this vote has happened, without overstating what the vote actually changed (nothing, yet).
